These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 36718587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
    Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T, Saeki S, Kawata T.
    PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
    Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M.
    Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group.
    Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
    [Abstract] [Full Text] [Related]

  • 12. Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD.
    Metzger CE, Swallow EA, Allen MR.
    Calcif Tissue Int; 2020 Apr; 106(4):392-400. PubMed ID: 31832725
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.
    Tokumoto M, Tokunaga S, Asada S, Endo Y, Kurita N, Fukagawa M, Akizawa T.
    PLoS One; 2022 Apr; 17(12):e0279078. PubMed ID: 36512619
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM.
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [Abstract] [Full Text] [Related]

  • 16. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
    Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM.
    Endocr Pract; 2008 Sep; 14(1):18-27. PubMed ID: 18238737
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Osteocytic Osteolysis in PTH-treated Wild-type and Rankl-/- Mice Examined by Transmission Electron Microscopy, Atomic Force Microscopy, and Isotope Microscopy.
    Hongo H, Hasegawa T, Saito M, Tsuboi K, Yamamoto T, Sasaki M, Abe M, Henrique Luiz de Freitas P, Yurimoto H, Udagawa N, Li M, Amizuka N.
    J Histochem Cytochem; 2020 Oct; 68(10):651-668. PubMed ID: 32942927
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.